Erlotinib is an oral agent thatreversibly binds to the intracellular tyrosine kinase domain of the HER1/EGFRthus blocking phosphorylation and inhibiting signal transduction [11].Initially studied in nonsmall cell lung cancer (NSCLC), phase II data showed aresponse rate (RR) of 12% in patients previously treated with platinum-basedchemotherapy [12, 13]. Here, EGFR is linked to non-small cell lung carcinoma.